IL6 and ovarian carcinoma: As widely demonstrated in ovarian cancer, IL-6 acts both locally, by conditioning the host immune response at the site of pathogen infection, and systemically, by altering energy metabolism, hematopoiesis, and nutritional status, as well as inducing severe endothelial damage, thereby negatively affecting patient prognosis [25, 26].